Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus - Wikidata - wikimedia - TriplyDB

Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus

Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus

http://www.wikidata.org/entity/Q41269406

about

Sensitization of Staphylococcus aureus to methicillin and other antibiotics in vitro and in vivo in the presence of HAMLET Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect")Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections.Daptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus.Gram-positive resistance: pathogens, implications, and treatment options: insights from the Society of Infectious Diseases Pharmacists.Antibiotic resistance in Staphylococcus aureus and its relevance in therapy.Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus.β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives.Penicillin Binding Protein 1 Is Important in the Compensatory Response of Staphylococcus aureus to Daptomycin-Induced Membrane Damage and Is a Potential Target for β-Lactam-Daptomycin Synergy Update on daptomycin: the first approved lipopeptide antibiotic.Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall.Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant β-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment.Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.CAMERA2 - combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial.Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections.Daptomycin and tigecycline: a review of clinical efficacy in the antimicrobial era.Antimicrobial therapy of Staphylococcus aureus bloodstream infection.Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model.In Vitro and In Vivo Synergy of the Oxadiazole Class of Antibacterials with β-Lactams.A current perspective on daptomycin for the clinical microbiologist.Daptomycin in bone and joint infections: a review of the literature.Molecular Bases Determining Daptomycin Resistance-Mediated Resensitization to β-Lactams (Seesaw Effect) in Methicillin-Resistant Staphylococcus aureus.Daptomycin: pharmacology and clinical use.Current medical management of diabetic foot infections.Staphylococcus aureus inactivates daptomycin by releasing membrane phospholipids.When sepsis persists: a review of MRSA bacteraemia salvage therapy.Resistance to Non-glycopeptide Agents in Serious Staphylococcus aureus Infections.Antibiotic Combinations with Daptomycin for Treatment of Staphylococcus aureus Infections.Daptomycin-β-Lactam Combinations in a Rabbit Model of Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Endocarditis.Clinical pharmacological approach for balancing the use of daptomycin and linezolid in comparison with that of vancomycin in the treatment of MRSA-related infections.Natural lipopeptide antibiotic tripropeptin C revitalizes and synergistically potentiates the activity of beta-lactams against methicillin-resistant Staphylococcus aureus.Efficacy of daptomycin-cloxacillin combination in experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus.A Novel Way of Treating Multidrug-resistant Enterococci.β-Lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus.Comparative efficacies of cloxacillin-daptomycin and the standard cloxacillin-rifampin therapies against an experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus Daptomycin In Vitro Activity against Methicillin-Resistant Staphylococcus aureus Is Enhanced by d-Cycloserine in a Mechanism Associated with a Decrease in Cell Surface Charge.

P2860

Q21133536-1D0BDCD5-1A9C-459A-B4E2-F477FD802928 Q28481497-5AB6B2E3-FF19-4852-A087-943A0EABB439 Q33299938-68134986-AA9C-4075-8697-3DCBFD8A4555 Q33879066-DEA9FDE5-76F1-48E4-8996-263FC8D42D74 Q34045273-BA059808-6E8C-43D7-872D-327D5A805BA5 Q35169018-84BC8C0E-B968-40F8-A08A-B85C7036C6B5 Q35771368-EAD7E8F0-6124-4FC9-8329-781684AF10B5 Q36188333-76BC8943-0AEA-4C4B-87B4-5BE8A324D8CC Q36283731-D04BAA5A-EB19-4EB6-99E1-EA9FC967D87C Q36364106-C4AEF487-9892-45D7-985A-B09E0962D599 Q36396117-BCDAAB98-79E1-453C-B497-098606A64EF2 Q36439093-C8E93A18-5E9B-4270-B31B-A694461AC801 Q36521880-20C62429-4C62-444D-AD9C-0C082476F564 Q36565462-26C51025-9C7A-42FD-B87B-0055424346BE Q36667027-F88AD22D-040C-4BC6-AA6A-813F62FD7ED7 Q36718474-1121AD70-AD2D-4770-A6DF-59431A8D7844 Q36748977-DA241A43-564C-441E-BCC3-8174418748B9 Q36777821-63161796-B452-41FD-8F1D-56F0ACE5FA77 Q36967265-6992D7B5-E20D-4B20-8976-C78B1A312DF2 Q36968150-740D8568-1740-4FB2-BC33-FBA3FCC64109 Q36970335-5F8CF821-50E9-4AD5-8E6D-7739ADE6D68F Q37023118-E02269E3-F819-4160-ACC1-ABC74C6E6F7F Q37203885-C252B085-2523-4999-922A-27A46E897DE3 Q37263289-E3A44804-1B1E-4517-98DD-DE905C2B6894 Q37319460-63C77102-33CF-444B-8C81-E6CD12673C2D Q37538754-83CFA103-515C-4AA2-97A3-D43E429C19E8 Q37693931-19463011-4A1C-4B65-A4FC-BCEBC67DB75D Q37809059-CA45BA12-567D-457A-B3E2-EB70475F4F61 Q38404983-CA2C1AB6-544A-49C8-9D37-F2AF95364074 Q38632488-0101E4DF-ABE5-4B87-8081-F2DF6BA4E0C6 Q39016281-1E6ECAA4-8D91-4D90-A15B-B52C8960011D Q40631566-9B971564-D836-47AD-8484-6B2F6CE3482D Q40709730-F7805058-0876-4829-8E8B-98C07ED920B4 Q40845477-54244F1E-F3A2-4C15-A97C-0CD831A3A6ED Q41546542-42F2FEFA-4BFF-47C3-9D4C-40616380475D Q42008069-96305F28-478C-4C13-B363-391F56F2CBF5 Q42064666-3BFD102E-95D6-4715-9DFF-5E915B60A85C Q42099202-9B943C0E-8922-436A-BF36-CDC0D64E39FB Q42209248-E037A25A-C0C7-4D36-9DB5-30453360D4C3 Q42573041-4B13DCAE-A596-4862-9BB7-A55674DDF34A

P2860

Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus

http://www.wikidata.org/entity/Q41269406

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Synergy of daptomycin with oxa ...... esistant Staphylococcus aureus

@en

type

label

Synergy of daptomycin with oxa ...... esistant Staphylococcus aureus

@en

prefLabel

Synergy of daptomycin with oxa ...... esistant Staphylococcus aureus

@en

P1433

Q41269406-46ABA055-FE0F-4409-9DDD-253EBB6DA286

P1476

Q41269406-BE4BA941-7C78-4529-83B9-FEAE0AFCB0E4

P2093

Q41269406-37ED36F0-8FC0-4DD9-9233-85CF111FAD75

Q41269406-CF895B19-9293-44C0-AAE0-0E4DEC1A5B2A

P2860

Q41269406-0D29697E-FD0D-448A-A791-49D4973B1853

Q41269406-277763EA-E85E-483C-9190-D9D70CFF01E6

Q41269406-49F4EFD9-48A8-4963-9934-8718AF6DE209

Q41269406-7AAF718C-A8E8-48BD-A190-83798D65A25C

Q41269406-A33C773E-C346-46B4-9859-996D9D168877

Q41269406-A815810E-75DA-4712-A70D-6CD7F910C984

Q41269406-B1CFD0BF-AC50-4AAD-BF01-E97D6A42B44D

Q41269406-CA22BB2F-86BC-4E65-8DAA-5E8D2075AAA9

Q41269406-CC05725B-D6DC-4D7E-95A6-EC41853843A7

Q41269406-CC3EBC64-3D34-40FB-94D6-FEB5BFB0835C

P304

Q41269406-784A0C18-27CE-47B3-A231-DDB152AAB0B7

P31

Q41269406-EE5D445C-544C-4504-AD01-0C6A59291EC6

P356

Q41269406-86A9CD76-AA25-4FEC-83B7-D2045F03AB2E

P407

Q41269406-0C4B5B71-1693-48D0-8F08-5F01DB6745A4

P433

Q41269406-C2A9FD99-7D41-48C7-BB7B-4D8B35CED8CC

P478

Q41269406-37CD20F0-9887-4605-8AFA-A64214E37E22

P577

Q41269406-CC9EA3DF-8270-4237-BA16-B4C3311F8ACD

P5875

Q41269406-A845682C-05CE-490A-B353-7FBD6080785D

P698

Q41269406-EE43BDEF-560E-40E9-938D-DC24DB38CD1C

P921

Q41269406-F339EE05-374B-42F2-BD51-EE89BB9DFAB9

P932

Q41269406-DC7E39E7-8411-46A0-A5D6-82ABEC908F5C

P356

AAC.48.8.2871-2875.2004

P1433

Antimicrobial Agents and Chemotherapy

P1476

Synergy of daptomycin with oxa ...... esistant Staphylococcus aureus

@en

P2093

Herbert J Houck

http://www.w3.org/2001/XMLSchema#string

Kenneth H Rand

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetic properties of beta-lactamase inhibitors.

Comparison of concentrations of sulbactam-ampicillin administered by bolus injections or bolus plus continuous infusion in tissues of patients undergoing colorectal surgery.

Development of daptomycin for gram-positive infections.

Transcription of the gene mediating methicillin resistance in Staphylococcus aureus (mecA) is corepressed but not coinduced by cognate mecA and beta-lactamase regulators.

Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus.

Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.

Clinical evaluation of piperacillin with observations on penetrability into cerebrospinal fluid.

Overview of acylureidopenicillin pharmacokinetics.

Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.

Successful treatment of persistent bacteremia due to vancomycin-resistant, ampicillin-resistant Enterococcus faecium.

P304

2871-2875

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.48.8.2871-2875.2004

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2004-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8436806

http://www.w3.org/2001/XMLSchema#string

P698

15273094

http://www.w3.org/2001/XMLSchema#string

P921

methicillin-resistant Staphylococcus aureus

P932

478518

http://www.w3.org/2001/XMLSchema#string